MUMBAI, India, Sept. 29 /PRNewswire/ — Sun Pharmaceutical
Industries Ltd. (Sun) (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:
SUNPHARMA, BSE: 524715) today announced the expiration of the
subsequent offering period to the tender offer by Sun’s subsidiary
Alkaloida Chemical Company Exclusive Group Ltd (Alkaloida) for all
outstanding Ordinary Shares of Taro Pharmaceutical Industries Ltd.
(Taro). Sun has been informed by Computershare, the Depositary for
the Offer, that as of 12:00 midnight New York City time on
September 28, 2010, a total of 29,382 Ordinary Shares had been
tendered pursuant to the tender offer representing approximately
0.07% of the outstanding Ordinary Shares. During the pendency
of the subsequent offering period, no additional shares have been
tendered. All tendered Ordinary Shares were accepted for
payment.
About Sun PharmaEstablished in 1983, listed since 1994 and
headquartered in India, Sun Pharma (Reuters: SUN.BO, Bloomberg:
SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international,
integrated, speciality pharmaceutical company. It
manufactures and markets a large basket of pharmaceutical
formulations as branded generics as well as generics in India, US
and several other markets across the world. In India, the
company is a leader in niche therapy areas of psychiatry,
neurology, cardiology, diabetology, gastroenterology, orthopedics
and ophthalmology. The company has strong skills in product
development, process chemistry, and manufacturing of complex API,
as well as dosage forms. More information about the company can be
found at www.sunpharma.com.
ContactsUday Baldota
Mira DesaiTel
+91 22 6645 5645, Xtn 605Tel
+91 22 6645 5645, Xtn 606Tel Direct
+91 22 66455605Tel Direct
+91 22 66455606Mobile
+91 98670 10529Mobile
+91 98219 23797E mail
‘/>”/>
